The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Association between elevated WBC counts and thrombotic events in polycythemia vera
Aaron Gerds, MD, MS, Cleveland Clinic, Cleveland, OH, discusses the association between elevated white blood cell (WBC) counts and thrombotic events in patients with polycythemia vera, based on an analysis of the REVEAL trial (NCT02252159). The findings reveal that a hematocrit below 45% and a WBC count over 12 billion cells per liter increases thrombotic risk. This suggests switching medication to bring WBC count down would be beneficial to patients. The analysis also found no association between elevated platelet counts and thrombotic risk. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
